{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=19", "query": { "condition": "Sclc", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 4014, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T13:52:40.235Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03137264", "title": "Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Other", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 44, "start_date": "2017-10-24", "completion_date": "2018-11-10", "has_results": false, "last_update_posted_date": "2019-11-07", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 20, "location_summary": "Anaheim, California • Los Angeles, California • Santa Rosa, California + 16 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "St. Helena", "state": "California" }, { "city": "Deerfield Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03137264" }, { "nct_id": "NCT05553834", "title": "PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Alirocumab and Cemiplimab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-05-16", "completion_date": "2026-11-01", "has_results": true, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 2, "location_summary": "Tampa, Florida • Durham, North Carolina", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05553834" }, { "nct_id": "NCT05277051", "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Remzistotug", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "GSK5764227", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2022-03-22", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 7, "location_summary": "San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277051" }, { "nct_id": "NCT07776353", "title": "Understanding New Cachexia Subtypes Through Observational Epidemiological Research", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Pancreatic Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Colorectal Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic health record review", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Physical functions assessments", "type": "OTHER" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2023-04-05", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 1, "location_summary": "Pleasanton, California", "locations": [ { "city": "Pleasanton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07776353" }, { "nct_id": "NCT02367781", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Squamous Non-Small Cell Lung" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 723, "start_date": "2015-04-16", "completion_date": "2021-01-18", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 57, "location_summary": "Springdale, Arkansas • Oakland, California • Roseville, California + 52 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367781" }, { "nct_id": "NCT01107444", "title": "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "LY2181308", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-05", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 9, "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107444" }, { "nct_id": "NCT00283634", "title": "A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "erlotinib and bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2005-08", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2011-02-17", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00283634" }, { "nct_id": "NCT02900664", "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "ACZ885", "type": "BIOLOGICAL" }, { "name": "CJM112", "type": "BIOLOGICAL" }, { "name": "TMT212", "type": "DRUG" }, { "name": "EGF816", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 283, "start_date": "2016-08-23", "completion_date": "2021-03-17", "has_results": false, "last_update_posted_date": "2022-03-29", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02900664" }, { "nct_id": "NCT02848872", "title": "Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2016-05", "completion_date": "2019-04-02", "has_results": false, "last_update_posted_date": "2019-09-25", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02848872" }, { "nct_id": "NCT01041781", "title": "Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2010-02", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2018-07-23", "last_synced_at": "2026-11-07T13:52:40.235Z", "location_count": 400, "location_summary": "Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041781" } ] }